RTI Surgical Inc  

(Public, NASDAQ:RTIX)   Watch this stock  
Find more results for rtix
+0.01 (0.28%)
After Hours: 3.59 0.00 (0.00%)
Jun 30, 4:37PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.55 - 3.63
52 week 2.81 - 7.48
Open 3.60
Vol / Avg. 0.00/175,108.00
Mkt cap 208.32M
P/E 20.61
Div/yield     -
EPS 0.17
Shares 58.03M
Beta 1.31
Inst. own 82%
Jul 28, 2016
Q2 2016 RTI Surgical Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 26, 2016
RTI Surgical Inc Annual Shareholders Meeting
May 23, 2016
RTI Surgical Inc at UBS Global Healthcare Conference
May 5, 2016
RTI Surgical Inc at Deutsche Bank Health Care Conference
Apr 28, 2016
Q1 2016 RTI Surgical Inc Earnings Release
Apr 28, 2016
Q1 2016 RTI Surgical Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 3.56% 5.28%
Operating margin 5.94% 8.72%
EBITD margin - 15.50%
Return on average assets 2.53% 3.93%
Return on average equity 3.39% 6.65%
Employees 1,169 -
CDP Score - -


11621 Research Cir
ALACHUA, FL 32615-6825
United States - Map
+1-386-4188888 (Phone)
+1-386-4180342 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company's business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.

Officers and directors

Curtis M. Selquist Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Brian K. Hutchison President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter F. Gearen M.D. Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Robert P. Jordheim Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Caroline A. Hartill Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Roger W. Rose Jr. Executive Vice President - Tissue-Based Implants, President - RTI Donor Services
Age: 55
Bio & Compensation  - Reuters
Thomas F. Rose CPA Corporate Secretary
Bio & Compensation  - Reuters
Thomas McEachin Director
Bio & Compensation  - Reuters
Jonathon M. Singer Director
Age: 51
Bio & Compensation  - Reuters
Christopher R Sweeney Director
Bio & Compensation  - Reuters